Hungary Richter to launch 'wonderdrug' on new market

Company signs exclusive license and supply agreement

EMA accepts new Richter contraceptive

To be sold in Europe and Russia

Richter is a top pick, share price may take off

Management considered overly conservative

Hungary Richter projects moderate revenue growth for 2020

Double-digit increase possible in U.S. and Western Europe

On-offs weigh on the results of Hungary's Richter

Fourth-quarter revenue rises to new record high

ANALYST VIEW - Erste raises target price for Hungary's Richter

Recommendation remains 'Accumulate'

Hungary Richter transfers shares to employee share programme

Almsot half a million shares

Richter employees may now sell their shares

Lock-up period expires

Hungarys' Richter revises 2019 estimates higher

Management turn more upbeat

Hungary Richter seen reporting record quarterly revenue

Profit expected to jump from low base

Hungary's Richter signs license and development agreement with Mycovia

For RVVC drug VT-1161

ANALYST VIEW - Jefferies sharply raises target price for Hungary's Richter

Rating upgraded to 'Buy' from 'Underperform'

Richter announces approval in Japan of its licensed-out biosimilar teriparatide

Hungarian drugmaker Richter projects slight growth in sales this year

With a 10% decrease in Russia and 20% in China

Vraylar sales in U.S. boost Richter Q2 result

Revenue rose 8.5% to HUF 120 billion.

Richter expected to post higher revenue, lower profit in Q2

Analysts forecast 30% lower net profit.

Drug makers could pay Hungary central budget HUF 100 bn in 2020

Hungary's Richter inks exclusive license deal for Australia, New Zealand

Richter to supply, Seqirus to sell.

Hungary Richter profit leaps in the first quarter of 2019

Revenues and profit overshoot estimates.

Hungary's Richter to report impressive profit growth for Q1

Earnings report to be released on 10 May.